Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
October 16, 2018 Humanized Mouse Models for Immunotherapy Research Humanized mouse models simulate real patient responses for the evaluation of immunotherapeutic drug candidates. This supports more translatable preclinical immuno-oncology research with deeper insight into an agent’s likely performance in clinical trials. LEARN MORE
October 11, 2018 Tumor Homograft Model Generation: Dissociated Tumor Cells vs Tumor Fragments Novel murine immunocompetent models are needed to overcome issues with commonly used syngeneic tumor models and ... LEARN MORE
October 9, 2018 Why PDX Are Needed for Metastatic Breast Cancer Research Metastatic breast cancer is currently incurable, though preclinical research is ongoing. Generating new therapies for ... LEARN MORE
October 5, 2018 Artificial Intelligence for Life Science Diagnostics There are multiple forms of artificial intelligence (AI), including deep learning, neural networks, Bayesian networks, ... LEARN MORE
October 3, 2018 Oncolytic Viruses in Cancer Therapy While viral therapy has existed conceptually for some time, it has only recently gained traction as a promising ... LEARN MORE
September 13, 2018 CAR-T Cell Therapy for Solid Tumors CAR-T cell therapies are currently only approved for blood cancers, but new preclinical research shows promise in using ... LEARN MORE
September 11, 2018 Using Plasma Ceramides to Predict Coronary Artery Disease Cardiovascular disease (CVD) is the number one cause of death globally, making improved prognostic disease indicators an urgent priority. Are ceramides a potential biomarker for our risk of CVD and coronary artery disease? LEARN MORE
September 4, 2018 Prostate Cancer Patient-Derived Xenograft (PDX) Models Clinically-relevant prostate cancer patient-derived xenograft (PDX) models are notoriously hard to generate. Here we ... LEARN MORE
August 31, 2018 Why Are Prostate Cancer Preclinical Models Hard to Develop? Prostate cancer is a particularly difficult cancer type to model for preclinical research. Why are prostate cancer ... LEARN MORE
August 17, 2018 Facilitating Drug Discovery with 3D In Vitro Oncology Models Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in ... LEARN MORE
August 7, 2018 Preclinical Research Models of NAFLD/NASH Most preclinical models of NAFLD/NASH are limited to studying specific aspects of the disease. In this blog post, you can review ideal applications for currently available NAFLD/NASH models and discover a new, more translatable choice for preclinical drug development. LEARN MORE
August 2, 2018 Are Noninvasive Tests Enough for NAFLD/NASH Diagnosis? There is significant interest in validating strategies for the noninvasive evaluation of fibrosis in NAFLD/NASH. This ... LEARN MORE
July 31, 2018 From Pathogenesis to Treatment with NAFLD/NASH Non-alcoholic steatohepatitis (NASH) is a hot topic in 2018, with a race to the first approved treatment well under way ... LEARN MORE
July 26, 2018 IDO to I DON’T – IDO1 Inhibitor Development News As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that ... LEARN MORE
July 24, 2018 Improving Cardiac Function with FTY720 – ADA 2018 Our ADA presentations this year included a collaborative poster with Pegasus Bio. The studies used our unique panel of ... LEARN MORE